Sylvia Cheng

Dr. Sylvia Cheng

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAna S. Guerreiro Stucklin
Ana S. Guerreiro Stucklin
SRScott Ryall
Scott Ryall
KFKohei Fukuoka
Kohei Fukuoka
MZMichal Zapotocky
Michal Zapotocky
ALAlvaro Lassaletta
Alvaro Lassaletta
CHCynthia Hawkins
Cynthia Hawkins
Infant gliomas have paradoxical clinical behavior compared to those in children and adults: low-grade tumors have a higher mortality rate, while high-grade tumors have a better outcome. However, we have little understanding of their biology and therefore cannot explain this behavior nor what constitutes optimal clinical management. Here we report a comprehensive genetic analysis of an international cohort of clinically annotated infant gliomas, revealing 3 clinical subgroups. Group 1 tumors arise in the cerebral hemispheres and harbor alterations in the receptor tyrosine kinasesALK,ROS1,NTRKandMET. These are typically single-events and confer an intermediate outcome. Groups 2 and 3 gliomas harborRAS/MAPKpathway mutations and arise in the hemispheres and midline, respectively. Group 2 tumors have excellent long-term survival, while group 3 tumors progress rapidly and do not respond well to chemoradiation. We conclude that infant gliomas comprise 3 subgroups, justifying the need for specialized therapeutic strategies.

7 January 2016 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
SCSylvia Cheng
Sylvia Cheng
JKJohn-Paul Kilday
John-Paul Kilday
NLNormand Laperriere
Normand Laperriere
LJLaura Janzen
Laura Janzen
JDJames Drake
James Drake
UBUte Bartels
Ute Bartels

1 February 2020 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
ALAndrea C. Lo
Andrea C. Lo
DHDavid Hodgson
David Hodgson
JDJennifer Dang
Jennifer Dang
STScott Tyldesley
Scott Tyldesley
EBEric Bouffet
Eric Bouffet
NLNormand Laperriere
Normand Laperriere

21 June 2011 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
SCSylvia Cheng
Sylvia Cheng
OTO Teuffel
O Teuffel
MEM C Ethier
M C Ethier
CDC Diorio
C Diorio
JMJ Martino
J Martino
LSLillian Sung
Lillian Sung
To describe (1) anticipated health-related quality of life during different strategies for febrile neutropaenia (FN) management and (2) attributes of those preferring inpatient management. Respondents were parents of children 0–18 years and children 12–18 years receiving cancer treatment. Anticipated health-related quality of life was elicited for four different FN management strategies: entire inpatient, early discharge, outpatient oral and outpatient intravenous (i.v.) therapy. Tools used to measure health-related quality of life were visual analogue scale (VAS), willingness to pay and time trade off. A total of 155 parents and 43 children participated. For parents, median VAS scores were highest for early discharge (5.9, interquartile range 4.4–7.2) and outpatient i.v. (5.9, interquartile range 4.4–7.3). For children, median scores were highest for early discharge (6.1, interquartile range 4.6–7.2). In contrast, the most commonly preferred strategy for parents and children was inpatient in 55.0% and 37.2%, respectively. Higher current child health-related quality of life was associated with a stronger preference for outpatient management. Early discharge and outpatient i.v. management are associated with higher anticipated health-related quality of life, although the most commonly preferred strategy was inpatient care. This data may help with determining more cost-effective strategies for paediatric FN.

28 November 2016 in Canadian Medical Association Journal
Verified
Journal Article
Closed access
PDF file
RGRan D Goldman
Ran D Goldman
SCSylvia Cheng
Sylvia Cheng
DCD. Douglas Cochrane
D. Douglas Cochrane
Central nervous system (CNS) tumours account for a quarter of all cancers in children aged 1 to 19 years, despite being relatively uncommon.[1][1] Survival in many cases is poor, and thus the diagnosis may be devastating.[2][2] Yet for 70% of children with CNS tumours, there is potential for

17 February 2012 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
OTO. Teuffel
O. Teuffel
SCSylvia Cheng
Sylvia Cheng
MEM. C. Ethier
M. C. Ethier
CDC. Diorio
C. Diorio
JMJ. Martino
J. Martino
SAShabbir Alibhai
Shabbir Alibhai